Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:advocacy |
informed consent obtained
|
| gptkbp:affiliated_with |
various universities and hospitals
|
| gptkbp:analysis |
statistical analysis
|
| gptkbp:business_model |
obtained
adhered to ethical standards |
| gptkbp:clinical_trial |
ASCEND-2 Trial
NCT02820478 |
| gptkbp:collaborator |
multiple hospitals
|
| gptkbp:collection |
2015-2020
questionnaires and medical records |
| gptkbp:committee |
independent oversight
|
| gptkbp:completed |
gptkb:2020
|
| gptkbp:concluded_on |
aspirin not recommended for primary prevention in diabetes
|
| gptkbp:criteria |
age 40-80
history of gastrointestinal bleeding |
| gptkbp:duration |
5 years
|
| gptkbp:enrollment_criteria |
adults with diabetes
|
| gptkbp:events |
up to 7 years
|
| gptkbp:focuses_on |
treatment of diabetes
|
| gptkbp:funding |
gptkb:health_services
funded by public health organizations |
| gptkbp:future_research_suggestions |
long-term effects of aspirin
|
| gptkbp:has_implications_for |
guides future cardiovascular research in diabetes
|
| gptkbp:has_limitations |
short follow-up for some participants
|
| https://www.w3.org/2000/01/rdf-schema#label |
The ASCEND Trial
|
| gptkbp:investigates |
gptkb:Professor_Jane_Armitage
|
| gptkbp:is_studied_in |
multicenter study
|
| gptkbp:is_tested_for |
Phase III
|
| gptkbp:location |
gptkb:United_Kingdom
|
| gptkbp:participant_count |
15,000
|
| gptkbp:participants |
cardiovascular events
mortality rates |
| gptkbp:patient_population |
adults with type 1 and type 2 diabetes
|
| gptkbp:prevention |
aspirin therapy
|
| gptkbp:primary_hypothesis |
aspirin reduces cardiovascular risk
|
| gptkbp:provides_guidance_on |
influenced diabetes management guidelines
|
| gptkbp:provides_information_on |
available upon request
|
| gptkbp:publication_year |
gptkb:2021
|
| gptkbp:randomization_method |
randomized controlled trial
|
| gptkbp:recruitment |
through general practices
|
| gptkbp:research_output |
aspirin showed no significant benefit
|
| gptkbp:result |
gptkb:The_Lancet
|
| gptkbp:side_effect |
minor bleeding
|
| gptkbp:sponsor |
gptkb:University_of_Oxford
|
| gptkbp:started_in |
gptkb:2015
|
| gptkbp:study_design_type |
prospective cohort study
|
| gptkbp:study_findings |
aspirin does not prevent heart disease in diabetes
|
| gptkbp:study_outcome_measures |
clinical endpoints and quality of life
|
| gptkbp:study_outcomes |
increased risk of bleeding in some patients
no significant reduction in heart attack no significant reduction in stroke no significant reduction in cardiovascular mortality |
| gptkbp:study_population_characteristics |
diverse demographic backgrounds
|
| gptkbp:study_results_publication |
published in peer-reviewed journal
|
| gptkbp:bfsParent |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:bfsLayer |
6
|